Multiple Myeloma Drugs Market Expansion Continues, with Forecast Valuation of $29.99 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Multiple Myeloma Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In the recent past, we've witnessed a significant increase in the size of the multiple myeloma drugs market. A rise from $21.84 billion in 2024 to $23.25 billion in 2025 is anticipated, marking a compound annual growth rate (CAGR) of 6.5%. Elements like improved diagnosis, successful clinical trials, enhanced understanding of disease biology, upgraded healthcare infrastructure, patient advocacy, and increased awareness have all contributed to the growth seen in the historic period.

Multiple Myeloma Drugs Market Size Forecast: What's the Projected Valuation by 2029?
The market for multiple myeloma drugs is anticipated to experience robust growth in the coming years, with its valuation expected to reach $29.99 billion in 2029 at a CAGR of 6.6%. The expected growth during the forecast period can be linked to advancements in immunotherapy, the growth of targeted therapies, the use of liquid biopsies, the development of car-t cell therapy, as well as biomarker discovery. Key trends expected during the forecast period include a greater emphasis on long-term survivorship, the exploration of epigenetic therapies, a more prominent role for telemedicine, increased access to novel therapies, and the quest for sustainability in myeloma treatment.

View the full report here:
https://www.thebusinessresearchcompany.com/report/multiple-myeloma-drugs-global-market-report

What Are the Drivers Transforming the Multiple Myeloma Drugs Market?
The expanding presence of blood-related cancers is anticipated to propel the momentum of the multiple myeloma drugs market. Hematological malignancies stem from blood-forming tissues like bone marrow or immune system cells, accounting for cancers like leukemia, lymphoma, multiple myeloma, among others. Medications designed for multiple myeloma are typically utilized for treating diverse myeloma types by eliminating and curbing the proliferation of cancer cells. These drugs work by diminishing cellular division, instigating a host of enzymatic responses, and helping to maintain bone strength while alleviating pain in deteriorating bones. Case in point, the American Cancer Society (ACS), a notable health organization committed to cancer eradication, recorded around 59,610 new instances of leukemia and nearly 20,380 occurrences of acute myeloid leukemia (AML) in January 2023. Furthermore, the death toll from leukemia summed up to about 23,710. As a result, the escalating occurrence of hematological cancer is steering the expansion of the multiple myeloma drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11943&type=smp

What Long-Term Trends Will Define the Future of the Multiple Myeloma Drugs Market?
The trend towards product innovation is becoming increasingly prevalent in the multiple myeloma drugs market. In order to solidify their market position and obtain a competitive edge, premiere companies are concentrating their efforts on creating new innovative products. Take for example, Janssen Biotech Inc., a biotech firm based in Japan. In March 2022, the company attained approval from the United States Food and Drug Administration for their innovative product, Carvykti - a CAR T-Cell therapy (or personalized immunotherapy) designed for multiple myeloma. Carvykti (ciltacabtagene autoleucel) is a cell-based product that has been genetically modified. It is made up of T cells that were transduced ex vivo with a disability replication lentiviral vector. This vector codes for an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) that includes two single domain antibodies linked to a 4-1BB costimulatory domain and a CD3-zeta signaling domain. This therapy is available to patients who have had at least four prior lines of treatment, including a regimen of three key types of multiple myeloma drugs-an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, and is used to remedy cases of relapsed conditions.

Which Segments in the Multiple Myeloma Drugs Market Offer the Most Profit Potential?
The multiple myeloma drugs market covered in this report is segmented -

1) By Drug Type: Immunomodulatory Drugs, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Monoclonal Antibody Drugs, Steroids, Other Drug Types
2) By Therapy: Targeted Therapy, Biologic Therapy, Chemotherapy, Other Therapies
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By End-User: Men, Women

Subsegments:
1) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide
2) By Proteasome Inhibitors: Bortezomib, Carfilzomib, Ixazomib
3) By Histone Deacetylase Inhibitors: Panobinostat, Romidepsin
4) By Monoclonal Antibody Drugs: Daratumumab, Elotuzumab, Isatuximab
5) By Steroids: Dexamethasone, Prednisone
6) By Other Drug Types: Alkylating Agents, Antimetabolites, New Experimental Drugs

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=11943&type=smp

Which Firms Dominate the Multiple Myeloma Drugs Market by Market Share and Revenue in 2025?
Major companies operating in the multiple myeloma drugs market include Pfizer Inc., Johnson & Johnson Pvt. Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG., Roche Holding AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kite Pharma Inc, Amgen Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company, Daiichi Sankyo Co. Ltd., Lonza Group AG, Cipla Ltd., ONO Pharmaceutical Co. Ltd., BieGene Ltd., Biotest AG, Onyx Pharmaceuticals Inc., PharmaMar SA, Karyopharm Therapeutics Inc., Poseida Therapeutics Inc., ImmunoGen Inc., Oncopetides AB

Which Regions Offer the Highest Growth Potential in the Multiple Myeloma Drugs Market?
North America was the largest region in the multiple myeloma drugs market in 2024. The regions covered in the multiple myeloma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11943

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.